cyrilzakka/clinical-trials huggingface dataset:
National Network Genomic Medicine Lung Cancer, Germany

Registry of the national Network Genomic Medicine Lung Cancer (nNGM), linking data on molecular diagnostics, clinical characteristics, treatment patterns and outcomes of subjects with non-small cell lung cancer (NSCLC) from 23 specialized cancer centres and more than 400 general hospitals and oncological practices in Germany

Within the national Network Genomic Medicine Lung Cancer (nNGM), comprehensive molecular diagnostics and treatment recommendations are provided by 23 certified cancer centres according to standardized procedures for patients with non-resectable NSCLC. More than 400 network partners across Germany (including hospitals and oncological practices) report data on subsequent treatment and outcomes to the nNGM registry. Clinical outcomes are continuously evaluated through analysis of data collected in a decentralized registry. The nNGM registry records the patient journey and course of the disease from first histologically confirmed diagnosis to death or loss to follow-up and comprises detailed data on demographic and clinical characteristics, molecular diagnostics (including comprehensive biomarker testing results), treatments (targeted therapy, immunotherapy, chemotherapy, radiotherapy, best supportive care) and outcomes (overall survival, response, disease progression, time to next treatment). Patients have been actively involved throughout all stages of the design and running of the network and its registry.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years
* Histologically confirmed, locally advanced or metastatic NSCLC (Union for International Cancer Control \[UICC\] stage IIIb/IV; non-resectable NSCLC)
* From 07/2023: histologically confirmed NSCLC stage Ib, II, III (UICC)

Exclusion Criteria:

* Missing written informed consent
Near-Infrared Spectroscopy in Myofascial Pain Syndrome

Myofascial pain syndrome is a regional pain syndrome accompanied by sensorial, motor and autonomic symptoms . myofascial trigger points are most frequently detected in the upper trapezius, levator scapula, and axial postural muscles such as rhomboid major. Myofascial pain syndrome is characterized by active myofascial trigger points in the form of focal hyperirritable nodules palpated in the tight band of the muscle .

Alteration of tissue vascularization could limit or prevent th may cause adhesions, contractures and pain. As a result of decreased blood flow, tissue oxygenation may decrease.

In this study, it will be tried to determine the role of muscle tissue oxygenation in the activity and diagnosis of the disease in myofascial pain syndrome.

Eligibility Criteria:
Inclusion Criteria:

* 18-65 years old
* myofascial pain syndrome

Exclusion Criteria:

* Cervical radiculopathy
* Fibromyalgia
* Shoulder joint disease,
* Peripheral and central nervous system disease
* Polyneuropathy,
* Inflammatory rheumatic disease,
* Malignancy
A Randomized, Open Label, Clinical Trial of the Pharmacokinetics of Azithromycin Following a Single Dose of Azithromycin Sustained Release (2 Gram) or Commercial Azithromycin Tablet (500 mg) to Cancer Patients That Require Lung Surgery

The objective of this trial was to characterize the pharmacokinetics of the currently marketed azithromycin immediate release tablet formulation (AZ-IR) versus the azithromycin sustained release liquid formulation (AZ-SR) in lung tissue and bronchial washings, the latter consisting of the epithelial lining fluid (ELF) and cellular elements, mainly alveolar macrophages (AM).


Eligibility Criteria:
Inclusion Criteria:

Inclusion criteria were hospitalized subjects diagnosed with lung cancer that had consented to surgery requiring lung resection who had a life expectancy of \>6 months.

Exclusion Criteria:

Key exclusion criteria were antibiotic prophylaxis prior to surgery, diffuse, non-infectious lung disease, history of cigarette smoking of \>5 packs per year, patients with any infectious disease that required antibiotic therapy, administration of drugs known to interfere with azithromycin pharmacokinetics, and subjects on chemotherapy.
Stroke COunseling for Risk REduction

The purpose of this study is to test the efficacy of the Stroke Counseling for Risk Reduction (SCORRE) intervention in increasing accuracy of perceived stroke risk and promoting lifestyle behavior change to reduce stroke risk in young adult African Americans.


Eligibility Criteria:
Inclusion Criteria:

* self-identify as African American/Black
* age 20-35 years
* able to complete two study visits lasing 1 1/2- 2 hours and a brief daily diary for 8 weeks
* has a cell phone or email address to receive weekly reminders and tips
* has at least one modifiable risk factor for stroke identified during study visit one screening
Clinical Validation of a Predictive Model for the Presence of Cervical Lymph Node Metastasis in Papillary Thyroid Cancer

This research study is performed to compare the accuracy of two methods of lymph node evaluation: research method versus standard method. Standard method is what is usually performed as standard of care where the radiologist evaluates the images overall and decides whether each node seen should or should not be biopsied. In the research method, a second radiologist will evaluate the ultrasound images of the lymph nodes separately, and use a small specific checklist of ultrasound appearance to determine whether each node should or should not be biopsied. Results of both the standard and research method will be used to decide which node(s), if any should be biopsied. Neck ultrasound examination, lymph node evaluation by standard method and subsequent lymph node biopsy are part of the standard clinical care. It is less likely but possible that the research method may identify additional lymph nodes for biopsy to check if that lymph node contains thyroid cancer.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of PTC and at least one sonographic examination of the cervical lymph nodes.
* Patients can only be included in the study once. Thus, if they have two sonographic examinations, only one can be included in the study results.
* All patients who fit the study criteria after the start of the study will be included, using the first sonographic exam as the study exam.

Exclusion Criteria:

* Lymph node with oval shape, hypoechoic cortex, smooth border, hyperechoic hilum and hilar Doppler flow by ultrasound are considered to be normal and be excluded from FNAB per standard clinical practice.
* Lymph node less than 5 mm in short axis on ultrasound.
Evaluating Xihuang Pill to Improve the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer

Evaluate the effectiveness of Xihuang Pill in improving the efficacy of neoadjuvant chemotherapy for breast cancer

1. To evaluate the safety and effectiveness of Xihuang Pill in improving the efficacy of neoadjuvant chemotherapy for breast cancer under the condition of widespread use.
2. To provide data support for improving the efficacy of neoadjuvant chemotherapy for clinical breast cancer patients.

Eligibility Criteria:
Inclusion Criteria:

1. Biopsy of breast mass was performed under ultrasound-guided treatment before neoadjuvant chemotherapy, and the diagnosis of breast cancer was confirmed pathologically, followed by immunohistochemical examination. Pathological sections before and after neoadjuvant chemotherapy were jointly diagnosed by 3 or more senior pathologists, and there were consistent definite conclusions.
2. Have detailed and complete clinicopathological data;
3. Diagnosis data of TCM syndrome type;
4. No biopsy-confirmed lymph node metastasis;
5. No serious systemic disease, able to tolerate neoadjuvant chemotherapy and surgical treatment;
6. At least 4 cycles of neoadjuvant chemotherapy were completed, and the efficacy of chemotherapy was evaluated at the end of chemotherapy and after surgery;
7. Under the guidance of doctors, take Xihuang pills in a standardized way throughout the whole process and review regularly;
8. The patient did not receive any antitumor therapy drugs associated with the tumor prior to neoadjuvant chemotherapy;
9. All patients were newly diagnosed

Exclusion Criteria:

1. Concurrent malignant tumors of other sites;
2. Patients with distant metastasis
3. Male breast cancer
4. Patients who did not receive full-course standardized neoadjuvant chemotherapy;
5. Lost contact or dropped out of the study, unable to follow up;
6. Inability to tolerate chemotherapy responses;
7. Intolerant to Xihuang Wan and unable to take it;
8. The patient has strong side effects of chemotherapy and cannot tolerate chemotherapy drugs;
9. Inflammatory breast cancer, bilateral breast cancer, paget's disease and other special types of breast cancer;
10. Various other possible influences.
Drug Delivery Via Pressurized Metered-dose Inhaler and Valved Holding Chamber in Asthmatic Children: Determination of Delivered Dose Following Coordinated and Uncoordinated Use

The primary objective of this study is to determine ex vivo the amount of fluticasone deposited onto a filter (delivered dose) interposed between the OptiChamber Diamond Valved Holding Chamber (VHC) mouthpiece and the subject's mouth during coordinated and uncoordinated actuation/inhalation maneuver.


Eligibility Criteria:
Inclusion Criteria:

* • Asthmatic children between the ages of 5 and 8 followed at Arkansas Children's Hospital.

  * The subjects must be available to complete the study.
  * The subject's parent(s) and/or the subject's legal guardian must provide written informed consent to participate in the study.
  * The subject must provide assent when older than 7 years old.
  * The subjects should have used a pMDI VHC previously and be able to use a VHC with mouthpiece.
  * The subjects should have been prescribed fluticasone or another inhaled corticosteroid delivered via a pMDI VHC combination.
  * Clinically stable asthma.
  * Cooperative, i.e., subject should be able to follow and understand instructions.
  * The subject must satisfy the study investigator about his/her fitness to participate in the study.

Exclusion Criteria:

* Clinically significant respiratory disease in the previous 4 weeks.
* Participation in any other clinical trial in the previous 4 weeks.
* Lack of cooperation, subject cannot follow and understand instructions.
A Study to Evaluate the Conformis Hip System

This is a prospective multicenter study. Subjects will be implanted with a Conformis Hip System. If the surgeon intraoperatively decides to use the Cordera femoral stem, these patients will also be enrolled in the study and tracked as a subset of the Conformis Hip System patient population.The study sites will be located in the United States. The study subjects will be followed for 10 years post implantation.


Eligibility Criteria:
Inclusion Criteria:

* Clinical condition included in the approved Indications For Use for the Conformis Hip System and the Cordera Hip System
* Osteoarthritis, as confirmed by the investigator's assessment of disease status at screening visit that warrants a THR procedure
* Willingness to participate in the clinical study, to give informed consent, and to attend all follow-up visits
* \> 18 years of age

Exclusion Criteria:

* Simultaneous bilateral procedure required
* BMI \> 40
* Poorly controlled diabetes (defined as HbA1c\>7 or Investigator discretion)
* Crowe classification of hip dysplasia, grades 2, 3, or 4
* Active malignancy (defined as a history of any invasive malignancy - except non-melanoma skin cancer), unless patient has been treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least 5 years
* Other lower extremity surgery planned within 1 year of consent to the affected limb Contralateral THR surgery within 3 months pre or post index surgery
* Neuromuscular conditions which prevent patient from participating in study activities
* Active local or systemic infection which precludes THR procedure
* Immunocompromised in the opinion of the Investigator
* Medically diagnosed fibromyalgia or similar conditions that might impact the patient's ability to differentiate source of pain
* Rheumatoid arthritis or other forms of inflammatory joint disease
* Loss of bone or musculature, osteonecrosis, neuromuscular or vascular compromise in the area of the joint to be operated on, to an extent that the procedure is unjustified
* Diagnosed with or receiving treatment for osteoporosis that is likely to confound results in the opinion of the Investigator
* Physical disability affecting the lumbar spine that is likely to confound results in the opinion of the Investigator
* Charcot or Paget's disease
* Inability to complete the protocol in the opinion of the clinical staff due to safety or other reasons
* Participation in another clinical study which would confound results
* Allergy to any of the implant materials
Somatization, Anxiety, and Disordered Sleep in Pediatric Eosinophilic Esophagitis

Eosinophilic esophagitis

In order to decrease disease burden and the perception of disease burden, investigators need to understand the symptoms and severity of anxiety, disordered sleep, and somatization and how these parameters align with symptoms and quality of life in pediatric EoE. To assess the burden of these parameters in children with EoE, investigators will conduct a single center pilot study of 60 children with EoE using validated indexes for anxiety (state trait anxiety inventory for children), somatization (children's somatization inventory), sleep (pediatric sleep questionnaire), coping (Connor-Davidson Resilience Score) symptoms (PEESSv2.0), and quality of life (PedsQL-EoE).

Eligibility Criteria:
Inclusion Criteria:

* Age 8-18 years old
* Ability to understand and complete the surveys and complete them in English
* Known diagnosis of EoE defined as \> 15 eosinophils per high power field. Patient can have active or inactive disease at the time of entry

Exclusion Criteria:

* \<8 or \> 18 years old
* Inability to read the surveys in English
* Concurrent gastrointestinal diseases such as inflammatory bowel disease or Celiac disease.
18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer

This study is being done to learn how 18F-FSPG PET/CT scan results may be related to the response to chemotherapy and radiation in patients with esophageal cancer.

PRIMARY OBJECTIVES:

I. Evaluate the ability of 18F-FSPG PET imaging to detect tumors in patients with esophageal cancer.

Eligibility Criteria:
Inclusion Criteria:

* \* ≥ 18 years of age

  * Patients with locally advanced esophageal cancer
  * Patients with untreated documented carcinoma of the esophagus that is \> 2 cm who are going to receive systemic therapy concurrently with radiation as primary therapy
  * Ability to provide written informed consent in accordance with institutional policies
  * Female subjects of childbearing potential must have a negative serum or urine pregnancy test within 1 week of the proposed investigational PET/CT scan(s) prior to injection of the investigational radiopharmaceutical

Exclusion Criteria:

* \* Body weight ≥ 400 pounds or body habitus or disability that will not permit the imaging protocol to be performed

  * Pregnant or lactating females
  * Have an allergy to intravenous contrast
  * eGFR \< 30
Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension

A phase 3 study to evaluate efficacy and safety of AGSAVI

A randomized, double-blind, multicenter, phase 3 study to evaluate efficacy and safety of AGSAVI for Inadequately Controlled with AGLS

Eligibility Criteria:
Inclusion Criteria:

* Hypertension patient who satisfied below condition at Visit 1.

  * patient who takes antihypertensive drug

    * 140mmHg \<= sitSBP \<= 200mmHg
  * patient who doesn't take antihypertensive drug

    * 160mmHg \<= sitSBP \<= 200mmHg
* Hypertension patient who satisfied below condition at Visit 2.

  * 140mmHg \<= sitSBP \<= 200mmHg at Visit 2
  * 130mmHg \<= sitSBP \<= 200mmHg at Visit 2(In high-risk patients)

Exclusion Criteria:

* Patient who have received 4 or more antihypertensive drug
* Patient with 20mmHg of difference in sitSBP or 10mmHg of difference in sitDBP between 2 times of BP measuring at Visit 1
* Patient with sitDBP \>= 120mmHg at Visit 1 or 2
* Patient with secondary hypertension
Rate of Blood Pressure Control Among Hypertensive Patients With Hemodialysis in Sohag University Hospital

The goal of this Cross-sectional study is to detect hypertensive patients with hemodialysis in Sohag University Hospital and controlled patients and noncontrolled patients. The main questions it aims to answer are:

1. What is the pattern of blood pressure control among patients receiving hemodialysis?
2. What are factors associated with successful blood pressure control?
3. What is the level of patient knowledge and awareness regarding blood pressure management?
4. What are the challenges and barriers faced by patients in achieving optimal blood pressure control? Participants Blood pressure calculated by taking the average of three consecutive days measurement.

1. Survey Type: Cross-sectional study.
2. Target Population: Patients undergoing hemodialysis.
3. Sample Size: The target sample size are all hypertensive patients in Sohag university hospital dialysis unit
4. Survey Method: person to person interview in dialysis units will be used for data collection.

Blood pressure calculated by taking the average of three consecutive days

* 1st day (Dialysis Day): - Blood pressure will be measured (pre dialysis, inter dialysis, post dialysis).
* 2nd day (Inter Dialytic Day): - Blood pressure will be measured two times (AM, PM).
* 3rd day (Dialysis Day): - Blood pressure will be measured (pre dialysis, inter dialysis, post dialysis).

Eligibility Criteria:
Inclusion Criteria:

- Participants must be

* 18 years or older.
* currently receiving hemodialysis.
* Hypertensive patients.

Exclusion Criteria:

* patients under 18 years old.
* Patients stopped hemodialysis.
* Patients with ESRD not receiving hemodialysis.
Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation

The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) in hepatitis C virus (HCV)-infected adults who are undergoing liver transplantation.


Eligibility Criteria:
Key Inclusion Criteria:

* HCV-infected, male and non-pregnant/non-lactating females, who are undergoing liver transplantation

Key Exclusion Criteria:

* Receiving an HCV-infected liver
* HIV or hepatitis B virus (HBV) co-infected

Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Impact of Heparin on the Need for Mechanical Ventilation in Neonates

This study is designed to test an incidental finding of a previous trial in which post hoc analysis showed that the rate of intensive care newborns requiring mechanical ventilation was lower in the group receiving heparin with the continuous infusion as compared to the placebo group.

Title: Randomized double blind trial comparing heparin and placebo as additives to continuous infusion in intensive care neonates for prevention of mechanical ventilation

Primary endpoint: Percentage of neonates requiring mechanical ventilation in both groups

Secondary endpoints: Duration of dependency on mechanical ventilation; major bleedings, incidence of heparin-induced thrombocytopenia and of anti-platelet factor 4/heparin antibodies

Eligibility Criteria:
Inclusion Criteria:

* Newborns \< day 28 of life
* Necessity for intensive care treatment
* Necessity for parenteral drug or fluid application for at least five days
* Informed consent of parents

Exclusion Criteria:

* Body weight \< 500g
* Mechanical ventilation directly after birth
* Major malformations
* Absolute indication for heparin
* Inborn hemorrhagic disease (e.g. hemophilia, von Willebrand disease)
* Cerebral bleeding or other major bleeding
* Platelet count \< 50,000/µl
Influence of Perfluorohexyloctane (NovaTears) on Tear Film Thickness in Patients With Mild to Moderate Dry Eye Disease

Patients with mild to moderate dry eye disease will be randomized to receive either NovaTears® or Hydrabak® eye drops as control.


Eligibility Criteria:
Inclusion Criteria:

* Men and women aged over 18 years
* History of dry eye disease for at least 3 months before the screening visit
* Be able and willing to follow instructions, including participation in all study assessments and visits
* Signed and dated written informed consent

Exclusion Criteria:

* Have any clinically significant slit-lamp findings at the screening visit that may include trauma, Steven Johnson syndrome, and/or in the opinion of the investigator may interfere with study parameters
* Participation in a clinical trial in the 4 weeks preceding the before the screening visit
* Active ocular allergies or ocular allergies that are expected to be active during the study period
* Pregnancy, planned pregnancy or lactating
* Known hypersensitivity to any component of the study medication
* Any medical or surgical history, disorder or disease such as acute or chronic severe organic disease